Meeting
2023 ASCO Annual Meeting
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.
Authors
Zhen-gang Yuan
Department of Oncology, Eastern Hepatobiliary Surgery Hospital, Shanghai, China
Zhen-gang Yuan , Tian-mei Zeng , Guang Yang , Cheng Lou , Wei Wei , Chen-jie Tao , Xi-yun Chen , Qin Han , Zhuo Cheng , Pei-pei Shang , Yu-long Dong , He-ming Xu , Lie-ping Guo , Dong-sheng Chen , Yunjie Song , Chuang Qi , Wanglong Deng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
ChiCTR2000036652
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4086)
DOI
10.1200/JCO.2023.41.16_suppl.4086
Abstract #
4086
Poster Bd #
407
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai
Poster
2022 ASCO Annual Meeting
Phase 1b results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- CPI-613 as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
First Author: Vaibhav Sahai
Poster
2018 ASCO Annual Meeting
A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.
First Author: Vaibhav Sahai
Poster
2018 Gastrointestinal Cancers Symposium
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer.
First Author: Vaibhav Sahai